Chemistry:Adebrelimab

From HandWiki

Adebrelimab is a drug that is being evaluated for the treatment of solid tumors. Adebrelimab is recombinant humanized IgG4 monoclonal antibody with specificity for PD-L1.[1][2]

In 2023, adebrelimab was approved for use in China for the treatment of small cell lung cancer.[3]

References

  1. ↑ "Adebrelimab plus chemotherapy vs. chemotherapy for treatment of extensive-stage small-cell lung cancer from the US and Chinese healthcare sector perspectives: a cost-effectiveness analysis to inform drug pricing". Frontiers in Pharmacology 14. 2023. doi:10.3389/fphar.2023.1241130. PMID 37547339. 
  2. ↑ "Adebrelimab - Atridia". AdisInsight. Springer Nature Switzerland AG. https://adisinsight.springer.com/drugs/800049434. 
  3. ↑ "New drugs approved by NMPA in 2023". 3 April 2024. https://globalforum.diaglobal.org/issue/april-2024/new-drug-approvals-in-china-reached-record-high-in-2023/list-of-new-drug-approvals-in-china/. 




Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:Adebrelimab&oldid=4177179"